Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
2023年10月26日 - 9:01PM
ビジネスワイヤ(英語)
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, announced that John J.
Kuch, senior vice president and chief financial officer, plans to
retire in March 2024, after a 23-year career with Xencor and over
40 years in corporate finance. Mr. Kuch will support the search for
a new chief financial officer and has agreed to enter into a
consulting agreement following a transition period.
“In October 2000, Xencor was a small start-up designing protein
sequences, and John joined us then as a finance director, leading
all financial functions. We subsequently grew through multiple
venture rounds, revenue-generating partnerships and several public
financings, and we now have the strong financial position that
enables our rich clinical-stage pipeline and leading XmAb® protein
engineering technology platforms. John notably kept us solvent
through the global financial crisis and almost single-handedly
completed all financial and accounting aspects for our challenging
but ultimately successful IPO in 2013,” said Bassil Dahiyat, Ph.D.,
president and chief executive officer at Xencor. “On behalf of
Xencor’s Board of Directors and our entire team, I would like to
thank John for his leadership and more than two decades playing a
critical role in our pursuit of creating and advancing new
medicines for patients.”
“It has been a privilege, an honor and a pleasure to work with
my bright and talented colleagues at Xencor on the development of
novel technologies and medicines that could improve patient lives.
Our growth from a research organization built around world class
protein engineering capabilities into a development-stage
organization, supported by successful capital financings and
revenues from multiple partner-marketed products, is an
accomplishment of which I’m incredibly proud,” said Mr. Kuch. “Over
the coming months, I look forward to supporting the search for an
experienced finance executive and subsequent transition of
responsibilities and oversight of several key supportive functions.
And I certainly plan to follow Xencor’s progress with confidence,
as the Company continues to advance the most promising candidates
in the pipeline.”
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
“potential,” “can,” “will,” “plan,” “may,” “could,” “would,”
“expect,” “anticipate,” “seek,” “look forward,” “believe,”
“committed,” “investigational,” and similar terms, or by express or
implied discussions relating to Xencor’s business, including, but
not limited to the quotations from Xencor's chief executive officer
and chief financial officer, our ability to find a suitable new
chief financial officer in a reasonable timeframe, the ability of
Mr. Kuch to provide consulting services after retirement and other
statements that are not purely statements of historical fact. Such
statements are made on the basis of the current beliefs,
expectations, and assumptions of the management of Xencor and are
subject to significant known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements and the timing of events to be materially different
from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance
or results. Such risks include, without limitation, the risks
associated with the process of discovering, developing,
manufacturing and commercializing drugs that are safe and effective
for use as human therapeutics and other risks, including the
ability of publicly disclosed preliminary clinical trial data to
support continued clinical development and regulatory approval for
specific treatments, in each case as described in Xencor's public
securities filings. For a discussion of these and other factors,
please refer to Xencor's annual report on Form 10-K for the year
ended December 31, 2022 as well as Xencor's subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, as amended to date. All forward-looking statements are
qualified in their entirety by this cautionary statement and Xencor
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026008383/en/
Charles Liles cliles@xencor.com 626-737-8118
For Media: Jason I. Spark Evoke Canale
jason.spark@evokegroup.com 619-849-6005
Xencor (NASDAQ:XNCR)
過去 株価チャート
から 4 2024 まで 5 2024
Xencor (NASDAQ:XNCR)
過去 株価チャート
から 5 2023 まで 5 2024